Cargando…

Pathophysiology and preventive strategies of anthracycline-induced cardiotoxicity

Cardiotoxicity is a well-known complication following treatment with anthracyclines. However, they are still widely used in chemotherapy for breast cancer, lymphoma, leukemia, and sarcoma, among others. Patient clinical characteristics, such as age, sex, comorbidities, anthracycline dose and infusio...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chung, Woo-Baek, Youn, Ho-Joong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Korean Association of Internal Medicine 2016
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4939510/ https://www.ncbi.nlm.nih.gov/pubmed/27378126 http://dx.doi.org/10.3904/kjim.2016.017

Ejemplares similares

Strategies to prevent anthracycline-induced cardiotoxicity in cancer survivors
por: Bansal, Neha, et al.
Publicado: (2019)

Neprilysin Inhibition in the Prevention of Anthracycline-Induced Cardiotoxicity
por: Sobiborowicz-Sadowska, Aleksandra M., et al.
Publicado: (2023)

Anthracycline-induced cardiotoxicity in the chemotherapy treatment of breast cancer: Preventive strategies and treatment
por: Cai, Fengfeng, et al.
Publicado: (2019)

Anthracycline Chemotherapy and Cardiotoxicity
por: McGowan, John V, et al.
Publicado: (2017)

Role of Oxidative Stress in the Mechanisms of Anthracycline-Induced Cardiotoxicity: Effects of Preventive Strategies
por: Carrasco, Rodrigo, et al.
Publicado: (2021)

Chemotherapy-Induced Cardiotoxicity: Pathophysiology and Prevention
por: CSAPO, MELINDA, et al.
Publicado: (2014)

Cardiotoxicity of Anthracyclines
por: Cardinale, Daniela, et al.
Publicado: (2020)

Anthracycline-induced cardiotoxicity and senescence
por: Booth, Laura K., et al.
Publicado: (2022)

Epigenetic Changes Associated With Anthracycline‐Induced Cardiotoxicity
por: Tantawy, Marwa, et al.
Publicado: (2020)

Dexrazoxane for Preventing Anthracycline Cardiotoxicity in Children with Solid Tumors
por: Choi, Hyoung Soo, et al.
Publicado: (2010)

Metformin to Prevent Anthracycline Cardiotoxicity?: That Would Be Sweet!
por: El-Rayes, Malak, et al.
Publicado: (2023)

Statins in anthracycline-induced cardiotoxicity: Rac and Rho, and the heartbreakers
por: Henninger, Christian, et al.
Publicado: (2017)

Risk Factors for Anthracycline-Induced Cardiotoxicity
por: Qiu, Shuo, et al.
Publicado: (2021)

Novel Therapeutics for Anthracycline Induced Cardiotoxicity
por: Vuong, Jacqueline T., et al.
Publicado: (2022)

Anthracycline-induced cardiotoxicity and the cardiac-sparing effect of liposomal formulation
por: Rahman, Atiar M, et al.
Publicado: (2007)

Racial Disparity in Anthracycline-induced Cardiotoxicity in Breast Cancer Patients
por: Balaji, Swetha, et al.
Publicado: (2023)

Harnessing Genomics to Predict and Prevent Anthracycline-Associated Cardiotoxicity
por: Sapkota, Yadav
Publicado: (2020)

Efficacy of Dexrazoxane in Preventing Anthracycline Cardiotoxicity in Breast Cancer
por: Macedo, Ariane V.S., et al.
Publicado: (2019)

Prevention of Anthracycline-Induced Cardiotoxicity: The Good and Bad of Current and Alternative Therapies
por: Sangweni, Nonhlakanipho F., et al.
Publicado: (2022)

Cardiotoxicity of Non-Anthracycline Cancer Chemotherapy Agents
por: Briasoulis, Alexandros, et al.
Publicado: (2022)

The role of neurohormonal blockers in the primary prevention of acute-, early-, and late-onset anthracycline-induced cardiotoxicity
por: Ayuna, Ahmed, et al.
Publicado: (2020)

The role of iron in anthracycline cardiotoxicity
por: Gammella, Elena, et al.
Publicado: (2014)

Updates in Anthracycline-Mediated Cardiotoxicity
por: Nebigil, Canan G., et al.
Publicado: (2018)

Metabolic Aspects of Anthracycline Cardiotoxicity
por: Russo, Michele, et al.
Publicado: (2021)

Genetics of Anthracycline-Associated Cardiotoxicity
por: Al-Otaibi, Talal Khalid, et al.
Publicado: (2022)

Anthracycline-Induced Cardiotoxicity: Remembering the Forgotten Ventricle
por: Liu, Jennifer E.
Publicado: (2020)

The Quest for an Early Marker of Anthracycline-Induced Cardiotoxicity
por: Ibanez, Borja, et al.
Publicado: (2022)

Cardiac MRI assessment of anthracycline-induced cardiotoxicity
por: Mabudian, Leila, et al.
Publicado: (2022)

Editorial: Novel mechanisms, imaging approaches, and management strategies for anthracycline-induced cardiotoxicity
por: Packard, René R. Sevag, et al.
Publicado: (2023)

Anthracycline-induced cardiotoxicity: A case report and review of literature
por: Chong, Esther G, et al.
Publicado: (2021)

Clinical and preclinical evidence of sex-related differences in anthracycline-induced cardiotoxicity
por: Meiners, Becky, et al.
Publicado: (2018)

Anthracycline-induced cardiotoxicity: targeting high-density lipoproteins to limit the damage?
por: Abrahams, Carmelita, et al.
Publicado: (2022)

Intracellular magnesium concentrations and acute anthracycline-induced cardiotoxicity.
por: Sartori, S., et al.
Publicado: (1991)

Mechanisms of Anthracycline-Induced Cardiotoxicity: Is Mitochondrial Dysfunction the Answer?
por: Murabito, Alessandra, et al.
Publicado: (2020)

Cardiotoxicity of anthracycline therapy: current perspectives
por: Valcovici, Mihaela, et al.
Publicado: (2016)

Anthracycline Cardiotoxicity: Prevalence, Pathogenesis and Treatment
por: Volkova, Maria, et al.
Publicado: (2011)

Coronary microcirculation damage in anthracycline cardiotoxicity
por: Galán-Arriola, Carlos, et al.
Publicado: (2021)

Current Views on Anthracycline Cardiotoxicity in Childhood Cancer Survivors
por: Sadurska, Elżbieta
Publicado: (2015)

Pediatric Anthracycline‐Induced Cardiotoxicity: Mechanisms, Pharmacogenomics, and Pluripotent Stem‐Cell Modeling
por: Tripaydonis, Anne, et al.
Publicado: (2019)

Anthracycline induced cardiotoxicity: biomarkers and “Omics” technology in the era of patient specific care
por: Moazeni, Shayan, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_4fpblhmpmhtcbi5aq6r5dvnujk